36 results on '"Hogan, William J."'
Search Results
2. Mast cell cytomorphology and treatment outcome in mast cell leukemia.
3. Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
4. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases
5. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients
6. Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib
7. A dynamic 3‐factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy
8. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.
9. Isolated T‐cell acute lymphoblastic leukemic optic disc infiltration
10. Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia
11. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes
12. Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy
13. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole
14. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis
15. Long-term outcome of pomalidomide therapy in myelofibrosis
16. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma
17. Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation
18. Clinical utility of fluorescence in situ hybridization‐based diagnosis of BCR‐ABL1 like ( P hiladelphia chromosome like) B ‐acute lymphoblastic leukemia
19. A phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
20. Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma
21. Phase 1/-2 study of pomalidomide in myelofibrosis
22. Is There a Role For Inhaled Nitric Oxide as a Rescue Therapy in Respiratory Failure Associated With Hematologic Malignancies?
23. Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis
24. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis
25. A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status
26. Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes
27. Clinical utility of fluorescence in situ hybridization‐based diagnosis of BCR‐ABL1 like (Philadelphia chromosome like) B‐acute lymphoblastic leukemia.
28. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis
29. High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia
30. Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma.
31. Long‐term outcome of pomalidomide therapy in myelofibrosis
32. Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis
33. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma
34. Phase1/-2 study of Pomalidomide in myelofibrosis
35. A Phase II study of153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
36. A Phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.